Skip to main content
OpenTrials
Completed

NCT Number: NCT05220345

Synergistic Effect of G-Eye Balloon for Behind the Folds Visualization With CADe (Discovery System) on Adenoma Detection Rate.

Colonoscopy is the gold standard for colorectal screening. The diagnostic accuracy of colonoscopy highly depends on the quality of inspection of the colon during the procedure. To increase detection new polyp detection systems based on artificial intelligence (AI) have been developed. However, these systems still depend on the ability of the endoscopist to adequately visualize the complete colonic mucosa, especially to detect smaller and more subtle lesions, or lesions hidden behind folds in the colon. With this study we want to combine a device to flatten the folds in the colon combined with an artificial intelligence system to further improve the detection rate of lesions during colonoscopy.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Radboud university medical center Nijmegen

Nijmegen, Gelderland, 6500 HB, Netherlands

About this study

Rationale: Colonoscopy is the gold standard for CRC screening. The adenoma detection rate (ADR) is the most important quality parameter for colonoscopy, because of its inverse association with the risk of interval CRC. Yet, the adenoma miss rate (AMR) in conventional colonoscopy is reported in meta-analyses to vary between 22-26%. The diagnostic accuracy of colonoscopy highly depends on the quality of inspection of the colonic mucosa during the procedure. To increase the adenoma detection rate (ADR), new polyp/adenoma detection systems based on artificial intelligence (AI) have been developed, i.e., computer assisted detection (CADe). However, these systems still depend on the ability of the endoscopist to adequately visualize the complete colonic mucosa, especially to detect smaller and more subtle lesions. Therefore, we hypothesize that ADR can further be improved by combining a CADe system, the Discovery system, with a behind the fold (BTF) visualization technique, the G-Eye.

Study design: International multicenter prospective interventional cohort, compared with a cohort from the Discovery II study (NL73127.091.20, trial code NL9135). All subjects will be undergoing colonoscopy with a combined BFT and CADe assisted approach. Outcomes will be corrected for confounders using regression modeling.

Study population: 194 Adult patients (>18 years) from 3 hospitals, scheduled for diagnostic, screening (non-iFOBT based), or surveillance colonoscopy. Exclusion criteria: inflammatory bowel disease (IBD), known polyp or tumor upon referral, therapeutic procedure (e.g. endoscopic mucosal resection), prior surgical resection of any portion of the colon, American Society of Anesthesiologists score of ≥3, Inadequately corrected anticoagulation disorders or anticoagulation medication use, inability to provide informed consent.

Main study endpoints: The primary objective of the present study is to compare ADR between CADe assisted and a combined BTF/CADe assisted colonoscopy. Secondary objectives include advanced neoplasia rate (including advanced adenomas and/or CRC), polyp detection rate, size and histopathology, mean number of polyps per patient, procedure times, bowel cleaning levels, adverse events, inter-operator variability.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Eligible patients who are scheduled for surveillance colonoscopy will undergo one BFT and CADe assisted colonoscopy. There will be no burden for participants regarding the colonoscopy procedure. Colonoscopy is a commonly performed procedure, and the overall serious adverse event rate is low with an estimated risk 2.8 per 1000 colonoscopies. The risk of experiencing a (serious) adverse event with G-Eye and Discovery guided colonoscopy is believed to be equivalent to conventional colonoscopy. The benefit for patients is a higher likelihood of lesion detection during colonoscopy.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients (>18 years)
  • Referred and scheduled for diagnostic, screening (non-iFOBT based), or surveillance colonoscopy.

Exclusion criteria

  • Inflammatory bowel disease (IBD)
  • Known polyp or tumor upon referral
  • Therapeutic procedure (e.g., endoscopic mucosal resection)
  • Prior surgical resection of any portion of the colon
  • American Society of Anesthesiologists score of ≥3
  • Inadequately corrected anticoagulation disorder or anticoagulation medication use
  • inability to provide informed consent.

Treatment and study plan

colonoscopy assisted by both balloon-Behind The Folds visualizing and Computer assisted detection (CADe)

Device

All participants will be subjected to a colonoscopy procedure, assisted by both G-eye balloon and the Discovery CADe system. Standard of care regarding the colonoscopy procedure will be applied to all study subjects. Any lesions detected during the procedure will be removed directly

Primary outcomes

  1. Adenoma Detection Rate (ADR)

    Time frame: 30 days after procedure

    Calculated as the number of patients in whom at least one adenoma is detected during the colonoscopy procedure, divided by the total number of patients that underwent the colonoscopy procedure.

Secondary outcomes

  1. Advanced adenoma detection rate (AADR).

    Time frame: 30 days after procedure

    calculated as the number of patients in whom at least one advanced adenoma is detected during the colonoscopy procedure, divided by the total number of patients that underwent the colonoscopy procedure

  2. Polyp Detection Rate

    Time frame: 30 days after procedure

    calculated as the number of patients in whom at least one polyp is detected during the colonoscopy procedure, divided by the total number of patients that underwent the colonoscopy procedure

  3. Sessile detection Rate

    Time frame: 30 days after procedure

    calculated as the number of patients in whom at least one SSL is detected during the colonoscopy procedure, divided by the total number of patients that underwent the colonoscopy procedure

  4. Indication specific ADR,

    Time frame: 30 days after procedure

    ADR specific for screening, diagnostic, or surveillance

  5. Mean number of adenomas detected per patient

    Time frame: 30 days after procedure

    Mean number of adenomas detected per patient

  6. Mean number of polyps detected per patient

    Time frame: 30 days after procedure

    Mean number of polyps detected per patient

  7. Number of sessile serrated lesions

    Time frame: 30 days after procedure

    Number of sessile serrated lesions

  8. Number of advanced adenomas (adenomas ≥ 10 mm and/or with a villous component and/or with HGD

    Time frame: 30 days after procedure

    Number of advanced adenomas (adenomas ≥ 10 mm and/or with a villous component and/or with HGD

  9. Size of the lesion subdivided in categories 0-5 mm, 6-10 mm, 10-20 mm, >20 mm

    Time frame: During procedure

    Size of the lesion subdivided in categories 0-5 mm, 6-10 mm, 10-20 mm, >20 mm

  10. Location of the lesion: cecum, ascending colon, transverse colon, descending colon, sigmoid, rectum;

    Time frame: During procedure

    Location of the lesion: cecum, ascending colon, transverse colon, descending colon, sigmoid, rectum;

  11. Morphological characteristics of the lesion using the Paris classification (Ip, Is, IIa, IIb, IIc, III)

    Time frame: During procedure

    Morphological characteristics of the lesion using the Paris classification (Ip, Is, IIa, IIb, IIc, III)

  12. Histopathological characteristics of the lesion according to the Vienna classification

    Time frame: 30 days after procedure

    Histopathological characteristics of the lesion according to the Vienna classification

  13. ADR of the first 20% of patients that have undergone colonoscopy by each endoscopist will be compared with the final 20% of patients in each arm to identify any changes in ADR throughout the trial

    Time frame: At end of study

    ADR of the first 20% of patients that have undergone colonoscopy by each endoscopist will be compared with the final 20% of patients in each arm to identify any changes in ADR throughout the trial

  14. Bowel cleansing

    Time frame: During procedure

    Using the Boston Bowel Prep Scale

  15. Cecal intubation rate (CIR)

    Time frame: During procedure

    Cecal intubation rate (CIR)

  16. Procedure times with both techniques (i.e., total procedure time, mean polypectomy time and withdrawal time)

    Time frame: During procedure

    Procedure times with both techniques (i.e., total procedure time, mean polypectomy time and withdrawal time)

  17. Severe) adverse events (S)AEs up to 30 days post-procedure

    Time frame: 30 days after procedure

    SAEs will be subcategorized into colonoscopy related, cardiac (cardiac ischemia, heart failure, arrhythmia, other) pulmonary (exacerbation COPD, infectious, other), neurological (stroke, cerebrovascular accident, bleeding, other), and other (surgical interventions etc.)

  18. Gloucester Comfort Scale score and analgesia use

    Time frame: During procedure

    Gloucester Comfort Scale score and analgesia use

  19. Post-colonoscopy surveillance intervals when applying European and US surveillance guidelines

    Time frame: 30 days after procedure

    Post-colonoscopy surveillance intervals when applying European and US surveillance guidelines

Sponsors and collaborators

Lead sponsor

Radboud University Medical Center

Other

Collaborators

  • PENTAX Europe GmbH

Registry information

Official study title

Synergistic Effect of G-Eye Balloon for Behind the Folds Visualization With Artificial Intelligence Assisted Polyp Detection (Discovery System) on Adenoma Detection Rate. 'Discovery III Study'

Acronym: DiscoveryIII

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Feb 2, 2022
Registry last updated
Aug 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.